Air Liquide’s letter to its shareholders

Business Lines - Colonne centrale

Sleep apnea: putting Air Liquide expertise to serve patients

Around the world, between 5% and 8% of the adult population suffers from Sleep Apnea Syndrome (SAS). To treat this widespread and often unrecognized condition, Air Liquide develops its technological expertise, as well as offering a real relationship with the patient and a complete support service. Dr Bruno Mauvais, Respiratory Marketing Director, Air Liquide Healthcare, explains…

Back to top
Live share price112.25
    a- A+